APOE and Alzheimer disease: In this study we found within a series of prospectively characterized and clinicopathologically confirmed AD cases, ApoE ε4 carriers had a significantly higher percentage of “frequent” scores for plaques and tangles when using the CERAD scale when compared to ApoE ε4 non-carriers in several regions of the brain.